Agreement permits GRI to market Agencourt's innovative solid phase reversible immobilisation technology within the UK, Irish and French scientific communities
GRI, an independent supplier of biotechnology products, has signed an exclusive distribution agreement with Agencourt Biosciences.
The agreement permits GRI to market Agencourt's innovative SPRI technology within the UK, Irish and French scientific communities.
Agencourt Bioscience is a provider of nucleic acid purification products.
Agencourt offers an array of SPRI-based nucleic acid purification kits for customers who wish to improve and automate their own sequencing and discovery initiatives.
Solid phase reversible immobilisation (SPRI) is a patented, high performance purification technology based on the selective immobilisation of nucleic acids onto magnetic microparticles.
SPRI allows for easy automation of nucleic acid purification without sacrificing superior performance.
Since its development, SPRI has been adopted by many of the largest genome research facilities, and to date has the largest validation set of any nucleic acid purification technology.
The complete Agencourt SPRI range of products will be sold by and is available immediately from GRI's BioEssentials sales division.
